3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.
By TheStreet Wire ,

Two out of the three major indices are trading lower today with the

Dow Jones Industrial Average

(

^DJI

) trading down 6 points (0.0%) at 17,753 as of Wednesday, Nov. 11, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,244 issues advancing vs. 1,682 declining with 165 unchanged.

The Drugs industry currently sits down 0.9% versus the S&P 500, which is down 0.1%. Top gainers within the industry include

Endo International

(

ENDP

), up 2.8%,

Allergan

(

AGN

), up 1.0%,

Eli Lilly and

(

LLY

), up 0.8%,

Shire

(

SHPG

), up 0.7% and

Johnson & Johnson

(

JNJ

), up 0.6%. On the negative front, top decliners within the industry include

Intercept Pharmaceuticals

(

ICPT

), down 7.8%,

Mallinckrodt

(

MNK

), down 4.2%,

Valeant Pharmaceuticals International

(

VRX

), down 3.4%,

Incyte

(

INCY

), down 2.8% and

AbbVie

(

ABBV

), down 2.1%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AstraZeneca

(

AZN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.38 (1.2%) to $32.10 on light volume. Thus far, 904,811 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $31.82-$32.10 after having opened the day at $31.92 as compared to the previous trading day's close of $31.72.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $79.8 billion and is part of the health care sector. Shares are down 9.9% year-to-date as of the close of trading on Tuesday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and disappointing return on equity. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Mylan

(

MYL

) is up $0.47 (1.0%) to $45.91 on light volume. Thus far, 2.4 million shares of Mylan exchanged hands as compared to its average daily volume of 8.3 million shares. The stock has ranged in price between $45.66-$46.43 after having opened the day at $45.66 as compared to the previous trading day's close of $45.44.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Mylan N.V., through its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. Mylan has a market cap of $22.2 billion and is part of the health care sector. Shares are down 19.4% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Mylan a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Mylan

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Mylan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Biogen

(

BIIB

) is up $2.89 (1.0%) to $300.11 on light volume. Thus far, 794,270 shares of Biogen exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $296.00-$303.30 after having opened the day at $297.94 as compared to the previous trading day's close of $297.22.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen has a market cap of $65.4 billion and is part of the health care sector. Shares are down 12.4% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts who rate Biogen a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Biogen

as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Biogen Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...